Credit Suisse Ag United Therapeutics Corp Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in United Therapeutics Corp stock. As of the latest transaction made, Credit Suisse Ag holds 78,277 shares of UTHR stock, worth $24.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

78,277

Previous 61,656 26.96%

Holding current value

$24.8 Million

Previous $13.6 Million 32.63%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$210.76 - $249.51 $3.5 Million - $4.15 Million	16,621 Added 26.96%	78,277 $18 Million
Q4 2023 Feb 08, 2024	BUY	$214.88 - $256.94 $442,223 - $528,782	2,058 Added 3.45%	61,656 $13.6 Million
Q3 2023 Nov 13, 2023	BUY	$211.82 - $248.24 $417,285 - $489,032	1,970 Added 3.42%	59,598 $13.5 Million
Q2 2023 Aug 11, 2023	BUY	$205.19 - $232.99 $3.62 Million - $4.11 Million	17,656 Added 44.17%	57,628 $12.7 Million
Q1 2023 May 10, 2023	SELL	$212.99 - $276.17 $302,871 - $392,713	-1,422 Reduced 3.44%	39,972 $8.95 Million

Q4 2022 Feb 13, 2023	BUY	$205.95 - $280.43 $635,973 - $865,967	3,088 Added 8.06%	41,394 $11.5 Million
Q3 2022 Nov 10, 2022	BUY	$203.3 - $244.17 $235,218 - $282,504	1,157 Added 3.11%	38,306 $8.02 Million
Q2 2022 Aug 12, 2022	SELL	$174.81 - $241.14 $304,519 - $420,065	-1,742 Reduced 4.48%	37,149 $8.75 Million
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $287,124 - $369,722	1,728 Added 4.65%	38,891 $6.98 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $1.01 Million - $1.18 Million	-5,465 Reduced 12.82%	37,163 $8.03 Million
Q3 2021 Nov 12, 2021	SELL	$179.86 - $214.88 $3.18 Million - $3.8 Million	-17,664 Reduced 29.3%	42,628 $7.87 Million
Q2 2021 Aug 16, 2021	SELL	$170.47 - $211.93 $2.47 Million - $3.07 Million	-14,492 Reduced 19.38%	60,292 $10.8 Million
Q1 2021 May 14, 2021	SELL	$153.94 - $174.85 $1.76 Million - $2 Million	-11,463 Reduced 13.29%	74,784 $12.5 Million
Q4 2020 Feb 12, 2021	SELL	$101.87 - $151.79 $253,758 - $378,108	-2,491 Reduced 2.81%	86,247 $13.1 Million
Q3 2020 Nov 13, 2020	BUY	$99.9 - $121.13 $240,659 - $291,802	2,409 Added 2.79%	88,738 $8.96 Million
Q2 2020 Aug 12, 2020	BUY	$92.74 - $125.82 $1.84 Million - $2.49 Million	19,812 Added 29.78%	86,329 $10.4 Million
Q1 2020 May 13, 2020	SELL	$79.39 - $115.35 $1.2 Million - $1.74 Million	-15,126 Reduced 18.53%	66,517 $6.31 Million
Q4 2019 Feb 12, 2020	BUY	$78.31 - $95.34 $2.61 Million - $3.17 Million	33,293 Added 68.86%	81,643 $7.19 Million
Q3 2019 Nov 12, 2019	SELL	$74.85 - $85.99 $432,183 - $496,506	-5,774 Reduced 10.67%	48,350 $3.86 Million
Q2 2019 Aug 14, 2019	SELL	$76.06 - $120.81 $2.57 Million - $4.08 Million	-33,752 Reduced 38.41%	54,124 $4.22 Million
Q1 2019 May 14, 2019	SELL	$107.15 - $126.84 $997,352 - $1.18 Million	-9,308 Reduced 9.58%	87,876 $10.3 Million
Q4 2018 Feb 13, 2019	SELL	$101.4 - $128.73 $3.03 Million - $3.85 Million	-29,899 Reduced 23.53%	97,184 $10.6 Million
Q3 2018 Nov 13, 2018	BUY	$113.81 - $129.46 $186,079 - $211,667	1,635 Added 1.3%	127,083 $16.3 Million
Q2 2018 Aug 14, 2018	BUY	$101.14 - $118.31 $1.26 Million - $1.47 Million	12,467 Added 11.03%	125,448 $14.2 Million
Q1 2018 May 15, 2018	SELL	$107.21 - $151.94 $565,103 - $800,875	-5,271 Reduced 4.46%	112,981 $12.7 Million
Q4 2017 Feb 14, 2018	BUY	$118.58 - $151.28 $1.65 Million - $2.11 Million	13,947 Added 13.37%	118,252 $17.5 Million
Q3 2017 Nov 14, 2017	BUY	$114.6 - $136.81 $937,771 - $1.12 Million	8,183 Added 8.51%	104,305 $12.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	96,122	96,122 $12.5 Million

Others Institutions Holding UTHR

# of Institutions

561

Shares Held

43.1M

Call Options Held

501K

Put Options Held

529K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $14.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account